Loading...
XASX
ARX
Market cap139mUSD
Aug 28, Last price  
0.57AUD
Name

Aroa Biosurgery Ltd

Chart & performance

D1W1MN
XASX:ARX chart
P/E
56.88
P/S
2.56
EPS
0.01
Div yield, %
Shrs. gr., 5y
3.89%
Rev. gr., 5y
35.09%
Revenues
Net income
CFO

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
IPO date
Jul 24, 2020
Employees
6
Domiciled in
NZ
Incorporated in
NZ

Valuation

No data to show